AKBA News and Press, Akebia Therapeutics Inc. From 06/20/23

2023-06-20 08:30:00 ET BranchOut Food ( BOF ) +36% Secures Major Supplier Contract with Walmart. DICE Therapeutics ( DICE ) +38% stock movers today: Nikola, Arcellx, DICE Therapeutics, Beam Global and more. VCI Global  ( VCIG ) +-6% To Distribute...

Akebia Announces Swissmedic Approval of Vafseo® (vadadustat) PR Newswire CAMBRIDGE, Mass. , June 20, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced that the Swiss Agency for Therapeutic Products (Swissme...

2023-06-13 07:11:47 ET Biopharmaceutical company, Akebia Therapeutics ( NASDAQ: AKBA ) said that Ellen Snow is joining as new senior VP, CFO and Treasurer, beginning on July 17, 2023. Ms. Snow will join Akebia from Pear Therapeutics, where she has serv...

2023-06-07 14:19:41 ET Penny stocks typically trade for less than $5 and generally belong to small companies often overlooked by mainstream investors. Yet, for those willing to navigate the inherent risks, these cheap stocks can offer a world of potential. One strategy that has gained t...

2023-06-02 09:30:53 ET Akebia Therapeutics ( NASDAQ: AKBA ) announced Friday that its subsidiary Keryx Biopharmaceuticals and licensing partner Panion & BF Biotech settled the last patent litigation related to generic versions of its kidney disease therapy Auryxia. Counterpa...

2023-06-01 11:20:38 ET In the world of investment, penny stocks hold a unique position. Often priced at $5 per share or less, these are typically shares of small-cap companies that trade at relatively low prices. This low cost of entry often appeals to many investors, enabling them to a...

2023-05-30 10:01:01 ET Gainers: HeartBeam ( BEAT ) +23% . Taro Pharmaceutical Industries ( TARO ) +22% . Akebia Therapeutics ( AKBA ) +19% . Corvus Pharmaceuticals ( CRVS ) +16% . Immix Biopharma ( IMMX ) +13% . Losers:...

2023-05-30 08:21:37 ET Akebia Therapeutics ( NASDAQ: AKBA ) announced Tuesday that the FDA denied its appeal over the agency's decision to reject the company's marketing application for kidney disease candidate vadadustat. However, the agency's Office of New Drugs (OND) has guid...

FDA Provides Akebia Therapeutics a Path Forward for Vadadustat PR Newswire FDA denies formal dispute resolution, but outlines path to resubmit NDA for dialysis-dependent patients without new clinical studies Akebia plans to request Type A meeting and then resubmit NDA ...

2023-05-29 08:11:16 ET Summary Akebia Therapeutics Inc. is rated a Strong Buy due to its overly discounted revenue and strong prospects in the large Chronic Kidney Disease market. The company's valuation should be at least $716 million, more than 3x its current valuation, consider...